We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The problem with potency.
- Authors
Scott, Christopher Thomas
- Abstract
The article presents information on side effects related to monoclonal antibodies used in therapeutics. As the $30 billion monoclonal antibody market moves from murine-based to chimeric and fully human products, it grows at a compounded clip of nearly 20% per year. John Shields, an immunologist and principal at the London, England branch of Abingworth Management Ltd., points out that the claims that antibodies have the advantage of being very specific to a target are misguided. Diseases of the immune system, such as rheumatoid arthritis, arise as a result of perturbations of tightly regulated and coordinated interaction between key signaling molecules, tissue and immune cells.
- Subjects
IMMUNOGLOBULINS; AUTOIMMUNE diseases; THERAPEUTICS; IMMUNE system; CLINICAL medicine; RHEUMATOID arthritis
- Publication
Nature Biotechnology, 2005, Vol 23, Issue 9, p1037
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0905-1037